Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site rash, Vaccination site swelling, Vaccination site warmth
Clinical narrative: rash on at the injection site; warm at the injection site; tender at the injection site; raised at the injection site; redness at the injection site; This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE RASH (rash on at the injection site), VACCINATION SITE WARMTH (warm at the injection site), VACCINATION SITE PAIN (tender at the injection site), VACCINATION SITE SWELLING (raised at the injection site) and VACCINATION SITE ERYTHEMA (redness at the injection site) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20a) for COVID-19 vaccination.     No Medical History Information was reported.     On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE RASH (rash on at the injection site), VACCINATION SITE WARMTH (warm at the injection site), VACCINATION SITE PAIN (tender at the injection site), VACCINATION SITE SWELLING (raised at the injection site) and VACCINATION SITE ERYTHEMA (redness at the injection site). At the time of the report, VACCINATION SITE RASH (rash on at the injection site), VACCINATION SITE WARMTH (warm at the injection site), VACCINATION SITE PAIN (tender at the injection site), VACCINATION SITE SWELLING (raised at the injection site) and VACCINATION SITE ERYTHEMA (redness at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant Concomitant medications were reported.   No Treatment information for the event was provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 22-Feb-2021 and was forwarded to Moderna on 23-Feb-2021.    This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE RASH (rash on at the injection site), VACCINATION SITE WARMTH (warm at the injection site), VACCINATION SITE PAIN (tender at the injection site), VACCINATION SITE SWELLING (raised at the injection site) and VACCINATION SITE ERYTHEMA (redness at the injection site) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20a) for COVID-19 vaccination.     No Medical History Information was reported.     On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE RASH (rash on at the injection site), VACCINATION SITE WARMTH (warm at the injection site), VACCINATION SITE PAIN (tender at the injection site), VACCINATION SITE SWELLING (raised at the injection site) and VACCINATION SITE ERYTHEMA (redness at the injection site). At the time of the report, VACCINATION SITE RASH (rash on at the injection site), VACCINATION SITE WARMTH (warm at the injection site), VACCINATION SITE PAIN (tender at the injection site), VACCINATION SITE SWELLING (raised at the injection site) and VACCINATION SITE ERYTHEMA (redness at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant Concomitant medications were reported.   No Treatment information for the event was provided.